Accuray Reports Q2 Revenue of $102.2M
Reports Q2 revenue $102.2M vs. $116.2M last year. "Over the past 90 days, I've met extensively with Accuray teams and customers across all major regions. Their insights have directly informed the decisive actions we've already taken - from reorganizing our commercial structure to refining our near-term product and service investment priorities. We moved quickly and with discipline across the four pillars we outlined publicly: commercial simplification, global functional alignment, elevation of service and product development, and cost-structure and footprint optimization," said CEO Steve La Neve. "While this transformation is in its early stages, the pace of execution, the alignment across the organization, and the level of accountability give me confidence that we are on the right trajectory. Our objectives remain clear: accelerate top-line growth, enhance our competitive position, expand profitability, and deliver sustainable long-term value for all of our stakeholders, building a stronger Accuray, and the momentum we are seeing reinforces the impact of the steps taken to date," added La Neve.
Trade with 70% Backtested Accuracy
Analyst Views on ARAY
About ARAY
About the author

- Executive Appointment: Accuray announced the appointment of Paul Miele as Chief Commercial Officer effective April 6, 2026, tasked with leading the global commercial organization to drive transformation and enhance execution, thereby improving market competitiveness.
- Extensive Experience: Miele brings nearly two decades of global commercial leadership experience in the medical technology sector, having previously served as Business Unit Leader at Johnson & Johnson MedTech, where he successfully reversed a revenue decline trend and achieved double-digit annual sales growth.
- Strategic Objectives: As Chief Commercial Officer, Miele will define and execute Accuray's global commercialization strategy across sales, marketing, pricing, and market access, aiming to enhance the company's commercial impact in over 70 countries worldwide.
- Commitment to Innovation: Accuray is dedicated to improving cancer treatment through continuous innovation, and Miele's addition is expected to further drive growth in systems and services sales, particularly in providing value-added solutions to customers.
- Executive Appointment: Accuray announced the appointment of Paul Miele as Chief Commercial Officer effective April 6, 2026, tasked with leading the global commercial organization to drive transformation and enhance execution, thereby improving overall commercial performance.
- Extensive Experience: Miele brings nearly two decades of global commercial leadership experience in medical technology, having successfully reversed revenue declines and achieved double-digit annual sales growth as Business Unit Leader at Johnson & Johnson MedTech's MONARCH™ robotic platform, demonstrating his capability in complex business environments.
- Strategic Objectives: As Chief Commercial Officer, Miele will define and execute Accuray's global commercialization strategy across sales, marketing, pricing, and market access, aiming to further strengthen the company's commercial impact in over 70 countries worldwide.
- Commitment to Innovation: Accuray is dedicated to improving cancer treatment through continuous innovation, and Miele's addition is expected to drive growth in systems and services sales, particularly in providing value-added solutions to customers, thereby reinforcing the company's market position.
- Transformation Overview: CEO Steve LaNeve highlighted Accuray's comprehensive transformation plan aimed at enhancing operating profitability by approximately $25 million annually through cost structure optimization and organizational realignment, targeting about $12 million in benefits for fiscal 2026.
- Declining Financial Performance: The company reported net revenue of $102.2 million for Q2, down 12% year-over-year, with product revenue at $45 million, a 26% decline, while service revenue showed resilience at $57.2 million, up 4% from the previous year.
- Guidance Reduction: Accuray lowered its fiscal 2026 revenue guidance to $440 million to $450 million and adjusted EBITDA guidance to $22 million to $25 million, reflecting ongoing volatility in China and external pressures such as tariffs.
- Market Risks and Challenges: Management acknowledged that ongoing tariffs and geopolitical instability pose challenges to demand patterns and margin performance, emphasizing the need to focus on consistent execution amid a more challenging global environment, despite strong service revenue and backlog.
- Earnings Announcement Schedule: Accuray (ARAY) is set to release its Q2 earnings on February 4th after market close, with consensus EPS estimate at -$0.11 and revenue forecast at $100.86 million, reflecting a 13.2% year-over-year decline.
- Historical Performance Review: Over the past year, Accuray has only beaten EPS estimates 25% of the time, while it has exceeded revenue estimates 75% of the time, indicating relative stability in revenue but poor EPS performance.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with one downward adjustment, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting market caution regarding the company's future performance.
- Latest Earnings Results: In Q1 2026, Accuray reported a GAAP EPS of -$0.18, missing estimates by $0.12, while revenue of $93.9 million exceeded expectations by $2.55 million, demonstrating resilience in revenue despite ongoing profitability pressures.

- Earnings Call Schedule: Accuray is set to hold a conference call on February 4, 2026, at 1:30 PM PT (4:30 PM ET) to report its Q2 FY2026 financial results, reflecting the company's commitment to transparency and investor communication.
- Dial-in Information: The call can be accessed via US number 1-833-316-0563 and international number 1-412-317-5747, indicating the company's effort to provide accessible participation channels for global investors, enhancing its appeal to international stakeholders.
- Replay Availability: A replay of the call will be available approximately one hour after its conclusion, with US number 1-855-669-9658 and international number 1-412-317-0088, conference ID 8587254, ensuring that investors who cannot attend live can still access critical information, thereby improving information accessibility.
- Webcast and Replay: The call will be live-streamed on the company's investor relations website and will remain available until the announcement of Q3 FY2026 results, showcasing Accuray's modernization in information dissemination and enhancing investor engagement.

- Strategic Transformation Initiated: Accuray has announced the first phase of its comprehensive strategic transformation plan aimed at enhancing accountability and cost control, with an expected annual profit increase of approximately $25 million, thereby strengthening the company's market competitiveness.
- Organizational Structure Optimization: The plan will streamline the commercial structure, centralize core functions, and elevate global service and product development heads to report directly to the CEO, reallocating resources to support sales growth.
- Layoffs and Outsourcing: The company anticipates a global headcount reduction of about 15%, with expected cost savings of approximately $12 million in fiscal 2026 achieved through layoffs and outsourcing non-core activities, further enhancing profitability.
- Restructuring Charges Expected: Accuray expects to incur around $11 million in restructuring charges during the second, third, and fourth quarters of fiscal 2026, primarily related to workforce reductions and facility consolidations, ensuring the smooth implementation of the transformation plan.








